Free Trial
Final Hours! MarketBeat All Access at $149 Until 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

IperionX (NASDAQ:IPX) Shares Gap Down - Here's Why

IperionX logo with Materials background
Image from MarketBeat Media, LLC.

Key Points

  • IperionX shares fell sharply, opening at $14.99 versus the prior close of $17.04 and last trading near $14.97.
  • Analyst sentiment remains mixed: B. Riley cut its price target to $34 while maintaining a Buy rating, Jefferies initiated coverage with a Buy rating and $26 target, and Weiss Ratings reiterated a Sell rating. Overall, analysts have a “Moderate Buy” consensus with an average target of $42.
  • The company reported a quarterly loss of $0.50 per share, while analysts expect a full-year loss of $0.13 per share. Institutional ownership remains limited at 2.76%, despite several funds increasing or initiating positions.
  • MarketBeat previews the top five stocks to own by November 1st.

IperionX Limited Sponsored ADR (NASDAQ:IPX - Get Free Report)'s stock price gapped down before the market opened on Friday. The stock had previously closed at $17.04, but opened at $14.99. IperionX shares last traded at $14.9650, with a volume of 43,146 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of IperionX in a research note on Thursday, October 15th. B. Riley Financial lowered their target price on shares of IperionX from $52.00 to $34.00 and set a "buy" rating for the company in a report on Wednesday, September 30th. Jefferies Financial Group initiated coverage on IperionX in a research report on Wednesday, September 2nd. They issued a "buy" rating and a $26.00 price objective on the stock. Finally, Roth Capital set a $53.00 price target on shares of IperionX in a research note on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $42.00.

Check Out Our Latest Analysis on IPX

IperionX Price Performance

The business's 50-day moving average price is $18.14 and its 200 day moving average price is $30.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.24 and a quick ratio of 2.95.

IperionX (NASDAQ:IPX - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.50) EPS for the quarter. Equities research analysts predict that IperionX Limited Sponsored ADR will post -0.13 EPS for the current year.

Institutional Investors Weigh In On IperionX

Institutional investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC lifted its holdings in IperionX by 69.9% in the 1st quarter. Private Advisor Group LLC now owns 63,111 shares of the company's stock worth $1,643,000 after buying an additional 25,964 shares during the period. DLD Asset Management LP purchased a new stake in IperionX in the first quarter worth approximately $260,000. Connective Capital Management LLC purchased a new stake in shares of IperionX during the 2nd quarter valued at about $160,000. Finally, GAMMA Investing LLC grew its holdings in IperionX by 40.3% during the second quarter. GAMMA Investing LLC now owns 1,681 shares of the company's stock valued at $50,000 after purchasing an additional 483 shares during the period. Hedge funds and other institutional investors own 2.76% of the company's stock.

IperionX Company Profile

(Get Free Report)

IperionX Limited NASDAQ: IPX is a critical minerals and advanced materials company focused on producing low-carbon titanium products in the United States. The company is developing domestic sources of titanium minerals and technologies intended to convert titanium feedstocks into titanium metal, powder and other advanced materials.

IperionX's primary development asset is the Titan Project in Tennessee, which contains titanium, zircon and other heavy mineral sands. The company is also developing proprietary processing technologies, including the Hydrogen-Assisted Metallothermic Reduction (HAMR) process and the Titanium Alloy Production (TAP) process, with the goal of manufacturing titanium products using less energy than conventional production methods and incorporating recycled titanium where practical.

The company targets customers in industries such as aerospace, defense, medical devices, automotive, consumer products and additive manufacturing.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in IperionX Right Now?

Before you consider IperionX, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IperionX wasn't on the list.

While IperionX currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines